CorrectSequence Therapeutics announces a groundbreaking gene-editing treatment targeting APOC3 for hyperlipidemia, marking a significant medical milestone.

CorrectSequence Therapeutics unveils remarkable results for CS-206, a cutting-edge therapy for sickle cell disease, showing effectiveness and safety.

CorrectSequence Therapeutics has unveiled the first gene editing treatment targeting APOC3 to combat hyperlipidemia, marking a major milestone in medical biotechnology.

CorrectSequence Therapeutics has announced the successful results of their innovative base editing therapy for sickle cell disease, yielding long-term freedom from crisis.

CorrectSequence Therapeutics has achieved significant success with its innovative CS-206 base-editing therapy for sickle cell disease, showing long-lasting effects.

CorrectSequence Therapeutics recently revealed promising results for its CS-206 therapy, showing long-lasting efficacy and safety in patients with sickle cell disease, free from vaso-occlusive crises.

CorrectSequence Therapeutics has reported positive outcomes from its innovative base-editing therapy for sickle cell disease, showing sustained efficacy and safety over 15 months.

CorrectSequence Therapeutics has achieved a groundbreaking milestone by successfully administering the first-ever gene-editing therapy targeting APOC3 for hyperlipidemia patients. This innovation could mean a significant shift in treatment protocols.

A new clinical study reveals how base editing therapy using tBE has achieved significant remission in patients with sickle cell disease and beta-thalassemia across diverse genetic backgrounds.

A groundbreaking study reveals the effectiveness of tBE-mediated base editing therapy in treating sickle cell disease and β-thalassemia. The results are promising across diverse genetic backgrounds, revolutionizing treatment options for patients.

A recent study reveals that tBE-mediated base editing therapy achieves consistent success in treating sickle cell disease and β-thalassemia across genetic backgrounds, showing promise for patients worldwide.

CorrectSequence Therapeutics’ CS-121 Completed Dosing of First Chylomicronemia Patient, Demonstrating Excellent Safety and Significant Efficacy SHANGHAI, Nov. 6, 2025 /PRNewswire/ — On November 6, 2025, Shanghai, China, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for the treatment of severe diseases, announced that the first patient in its Investigator-Initiated Trial (IIT) of the base-editing therapy CS-121 […]

Five people with beta thalassemia who had their blood stem cells genetically altered no longer require regular blood transfusions to stay healthy. Their Chinese-made treatment is likely to be cheaper,...

CorrectSequence Therapeutics has made a historic innovation by administering the first gene-editing therapy aimed at treating hyperlipidemia. Learn more about this groundbreaking advancement.

CorrectSequence Therapeutics introduces the world's first gene-editing therapy targeting APOC3, marking a significant breakthrough in hyperlipidemia treatment.

CorrectSequence Therapeutics has reported promising outcomes in a patient treated for sickle cell anemia with their precision base editing therapy CS-101, showcasing new hope for patients.

A groundbreaking treatment for sickle cell disease, CS-101 from CorrectSequence Therapeutics, achieves significant success in a clinical trial involving a young patient, presenting a potential breakthrough.

CorrectSequence Therapeutics reports remarkable success in its CS-101 treatment for sickle cell disease, showing hope for patients worldwide.

CorrectSequence Therapeutics announces promising results from its CS-101 treatment for sickle cell disease, showcasing the potential of base editing technology.

CorrectSequence Therapeutics has achieved a significant milestone in sickle cell disease treatment with CS-101, demonstrating promising results in the first patient.

CorrectSequence Therapeutics has reported transformative results from its CS-101 gene editing therapy for sickle cell disease, marking a significant advancement in treatment.